Rsp5/NEDD4 and ESCRT regulate TDP-43 toxicity and turnover via an endolysosomal clearance mechanism
A pathological hallmark in >97% of amyotrophic lateral sclerosis (ALS) cases is the cytoplasmic mislocalization and aggregation of TDP-43, a nuclear RNA-binding protein, in motor neurons. Driving clearance of cytoplasmic TDP-43 reduces toxicity in ALS models, though how TDP-43 clearance is regulated remains controversial. We conducted an unbiased yeast screen using high-throughput dot blotting to identify genes that affect TDP-43 levels. We identified ESCRT complex genes, which induce membrane invagination (particularly at multivesicular bodies; MVBs) and genes linked to K63 ubiquitination (particularly cofactors of the E3 ubiquitin ligase Rsp5; NEDD4 in humans), as drivers of TDP-43 endolysosomal clearance. TDP-43 colocalized and bound Rsp5/NEDD4 and ESCRT proteins, and perturbations to either increased TDP-43 aggregation, stability, and toxicity. NEDD4 also ubiquitinates TDP-43. Lastly, TDP-43 accumulation induces giant MVB-like vesicles, within which TDP-43 accumulates in a NEDD4-dependent manner. Our studies shed light on endolysosomal-mediated cytoplasmic protein clearance, a poorly understood proteostasis mechanism, which may help identify novel ALS therapeutic strategies.
Authors
- Sophia Marcinowski
- Aaron Byrd (ORCID: https://orcid.org/0000-0002-5300-1264)
- Lucas J. Marmorale (ORCID: https://orcid.org/0000-0001-8926-4368)
- Sami J. Barmada (ORCID: https://orcid.org/0000-0002-9604-968X)
- Vanessa Addison
- Megan M. Dykstra (ORCID: https://orcid.org/0000-0002-4551-2478)
- J. Ross Buchan
Institutions
- University of Arizona (US)
- University of Michigan (US)
- AstraZeneca (Netherlands) (NL)
- Michigan Medicine (US)
- AstraZeneca (Japan) (JP)
Publication Details
- Journal
- The Journal of Cell Biology
- Published
- 2025-10-25
- DOI
- https://doi.org/10.1083/jcb.202212064
- Citations
- 1
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 1.39